RECQL4 helicase is a molecular motor that unwinds DNA, a process essential during DNA replication and DNA repair. Germ-line mutations in RECQL4 cause type II RothmundThomson syndrome (RTS) characterised by a premature aging phenotype and cancer predisposition. RECQL4 is widely considered as a tumour suppressor, although its role in human breast cancer is largely unknown. As the RECQL4 gene is localized to chromosome 8q24, a site frequently amplified in sporadic breast cancers, we hypothesised that it may play an oncogenic role in breast tumorigenesis. To address this we analysed large cohorts for gene copy number changes (n=1977), mRNA expression (n=1977) and protein level (n=1902).
INTRODUCTION
DNA helicases are molecular motors that unwind DNA, an essential process required during DNA replication and DNA repair. RecQ Protein-Like 4 (RECQL4) is a key member of the RecQ family of DNA helicases and plays an important role in the maintenance of genomic stability [1] [2] [3] . RECQL4 has a role in the initiation of DNA replication, progression of stalled replication forks, telomere maintenance and in repair of DNA double-strand breaks (DSBs) via the homologous recombination (HR) pathway [1] [2] [3] . Mutations in the RECQL4 gene are found in about two-thirds of all cases of Rothmund-Thomson syndrome (RTS), and these patients are designated as having Type II RTS [4, 5] . RTS is characterised by a premature aging and predisposition to cancers, especially lymphomas and osteosarcomas [4, 5] . A tumour suppressor function of RECQL4 has been widely described, although recent evidence also suggests a tumour-promoting role for RECQL4. In preclinical studies, we have recently found overexpression of RECQL4 in prostate cancer cell lines, and depletion of RECQL4 by siRNA or shRNA vectors significantly reduced the growth and survival of metastatic prostate cancer cells [6] . Similarly, in breast cancer cell lines, we have observed overexpression of RECQL4, and found that depletion of RECQL4 promoted apoptosis [7] . Interestingly, the RECQL4 gene is localized to chromosome 8q24, a site frequently amplified in sporadic breast cancers [8] [9] [10] . We therefore hypothesised a tumour-promoting role for RECQL4 in breast cancers.
MATERIALS AND METHODS

RECQL4 gene copy number changes and mRNA levels:
The METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort [11] was evaluated for RECQL4 gene copy number changes and mRNA levels. Patient demographics are summarized in supplementary Table S1 and full methods are discussed in Supplementary Methods online.
RECQL4 protein expression in breast cancer:
The study was performed in two cohorts of breast cancers. The first cohort was a consecutive series of 1,650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999. The second cohort was an independent series of 252 ER-α negative invasive breast cancer patients diagnosed and managed at the Nottingham University Hospitals between 1999 and 2007.
Immunohistochemical evaluation of RECQL4 is summarized fully in Supplementary methods and Supplementary Table S6 . Tumour Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al [12] , were followed throughout this study. Ethical approval was obtained from the Nottingham Research Ethics Committee (C202313).
Breast cancer assessment in RTS patients:
Incidence of breast cancer was evaluated among a cohort of RTS patients enrolled in a longitudinal clinical research study approved by the Institutional Review Board for Human Subjects Research at Baylor College of Medicine (Houston TX). All subjects or parents provided informed written consent to participate in the study. Clinical information was updated by yearly questionnaires. RTS patients with known mutations in the RECQL4 gene (Type II RTS) were included in the present study (n=58).
Patient demographics are shown in Supplementary Table S7 .
Cell line studies: HeLa, MCF7, MDA-MB-231 and BT549 lines were obtained from the ATCC (Manassas, VA, USA). Detailed methodology for Western blotting and imunofluorescence is summarised in Supplementary methods. We generated transient RECQL4 knockdown as well as stable RECQL4 knockdowns in breast cancer cells as described in Supplementary Methods. Cell numbers were estimated by the MTT assay according to the manufacturer's protocol. To evaluate replication dynamics, DNA fibre assays were performed as described previously [13] . Detailed methodology is also described in Supplementary Methods.
RESULTS AND DISCUSSION
We have recently shown that RECQL4 gene amplification and elevated levels of RECQL4 expression are common in breast cancer cell lines [7] . Moreover, depletion of RECQL4 not only reduced breast cancer cell proliferation but also impaired tumourigenicity in tumour bearing mice [7] . These data therefore support that RECQL4 may be oncogenic and drive breast tumourigenesis. To test this hypothesis, we conducted a comprehensive clinical study. Figure 1B) . Within the various molecular phenotype groups, compared to normal phenotype, tumours that were PAM50.Basal (p<0.00001), or PAM50.HER2 (p<0.00001) had high RECQL4 mRNA levels ( Figure 1C ). High levels of RECQL4 mRNA were highly significantly associated with aggressive clinicopathological features (Table 1) including high histological grade, lymph node positivity, larger tumour size, Nottingham prognostic index (NPI) >3.4, and triple negative phenotype (each, p<0.001). High RECQL4 mRNA level was also found to be significantly associated with previously described Table S6 ). Figure 2A , there was a strong correlation between gene copy number changes and mRNA levels (p<0.00001). The correlation remains significant across various sub-groups including in ER-(p<0.0001), ER+ (p<0.0001), PAM50.Basal Figures S1C and S1D ). Taken together the data supports that in a proportion of aggressive tumours, a high mRNA level is due to increased gene copy number.
Mechanistic insights: As shown in
RECQL4 protein level in breast cancers:
The N-terminal region of RECQL4 contains the nuclear as well as mitochondrial targeting sequences and is important for sub-cellular localisation of RECQL4 [1] [2] [3] . In addition, post-translational modification (such as acetylation) of RECQL4 may also alter its sub-cellular localisation [1] [2] [3] . As expected, we observed complex sub-cellular localisation of RECQL4 in human breast cancers including exclusively nuclear staining (17.6%), exclusively cytoplasmic staining (23.4%), nuclearcytoplasmic co-expression (24.8%) or absence of staining (34.2%) (Supplementary Figure   S1E) . In 20 normal breast tissues, however, we observed exclusively nuclear staining in all samples and no cytoplasmic staining (Supplementary Figure S1E) implying that altered subcellular localisation is a feature of cancer and not normal tissue. Tumours with high cytoplasmic/low nuclear RECQL4 levels were significantly associated with high grade, high mitotic index, pleomorphism, NPI>3.4, ER-, and triple negative phenotype (all p values <0.01) (Supplementary Table S7 ) and poor survival (p=0.042) ( Figure 2B ). In multivariate analysis the RECQL4 protein level independently influenced survival (p=0.032) (Supplementary Table S8 ).
Breast cancer incidence in patients with Rothmund-Thomson Syndrome (RTS):
Germline mutation in RECQL4 is causal for two-thirds of patients with Type II RTS, and it has previously been shown that RECQL4 mutation status correlates with risk of developing osteosarcoma [4, 5] . In the largest available cohort of type II RTS patients, we did not observe any increased incidence of breast cancers. The data suggests that either RECQL4 deficiency does not influence breast cancer pathogenesis or that RTS patients have not lived long enough to develop breast cancer.
Depletion of RECQL4 significantly reduced DNA replication rates and increased sensitivity to chemotherapy: DNA synthesis rates were measured using a DNA fibre assay after BrdU incorporation in MCF7, MDA-MB-231 and BT549 breast cancer cell lines plus or minus control siRNA or siRNA to deplete RECQL4 (Supplementary Figure S2) . We consistently observed shorter DNA fibre lengths after depletion of RECQL4 in the breast cancer cells (Figure 2C and 2D) . We then generated a stable RECQL4 knock down ER-(MDA-MB-453) breast cancer cell line ( Figure 3A) . As shown in Figures 3B-3D, RECQL4 depleted breast cancer cells were sensitive to treatment with cisplatin, doxorubicin or 5-FU.
In conclusion, we have demonstrated that high copy number, high mRNA levels and high protein levels of RECQL4 is associated with aggressive breast cancers. Although the data suggest to us that RECQL4 has oncogenic potential, it is also possible that RECQL4 overexpression may be a secondary event that may allow cancer cells to maintain high proliferation rate and telomere elongation required for cancer cell survival. shRNA of RECQL4, chemo-sensitization studies, VB; siRNA of RECQL4, DNA fibre assay, data analysis, interpretation, SM; study design, data analysis and interpretation.
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